Shields JA, Shields CL, Donoso LA. Management of posterior uveal melanoma. Surv Ophthalmol. 1991;36(3):161–95.
Article
CAS
PubMed
Google Scholar
Rantala ES, Hernberg M, Kivelä TT. Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Res. 2019;29(6):561–8.
Article
PubMed
PubMed Central
Google Scholar
Khoja L, Atenafu EG, Suciu S, Leyvraz S, Sato T, Marshall E, et al. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. Ann Oncol. 2019;30(8):1370–80.
Article
CAS
PubMed
Google Scholar
Küsters-Vandevelde HVN, Küsters B, Van Engen-van Grunsven ACH, Groenen PJTA, Wesseling P, Blokx WAM. Primary melanocytic tumors of the central nervous system: a review with focus on molecular aspects. Brain Pathol. 2015;25(2):209–26.
Article
CAS
PubMed
PubMed Central
Google Scholar
Singh AD, Shields CL, Shields JA, Sato T. Uveal melanoma in young patients. Arch Ophthalmol (Chicago, Ill : 1960). 2000;118(7):918–23.
CAS
Google Scholar
Kaliki S, Shields CL. Uveal melanoma: relatively rare but deadly cancer. Eye. 2017;31(2):241–57.
Article
CAS
PubMed
Google Scholar
Stålhammar G, See TR, Filì M, Seregard S. No gender differences in long-term survival after brachytherapy of 1,541 patients with uveal melanoma. Ocular Oncol Pathol. 2019;5(6):432–9.
Article
Google Scholar
Hu D-N, Yu G-P, McCormick SA, Schneider S, Finger PT. Population-based incidence of uveal melanoma in various races and ethnic groups. Am J Ophthalmol. 2005;140(4):612.e1–8.
Article
Google Scholar
Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011;118(9):1881–5.
Article
PubMed
Google Scholar
Virgili G, Gatta G, Ciccolallo L, Capocaccia R, Biggeri A, Crocetti E, et al. Incidence of uveal melanoma in Europe. Ophthalmology. 2007;114(12):2309–2315.e2.
Article
PubMed
Google Scholar
Aronow ME, Topham AK, Singh AD. Uveal melanoma: 5-year update on incidence, treatment, and survival (SEER 1973-2013). Ocular Oncol Pathol. 2018;4(3):145–51.
Article
Google Scholar
Stålhammar G, Herrspiegel C. Long-term relative survival in uveal melanoma: a systematic review and meta-analysis. Commun Med. 2022;2(18).
Jager MJ, Shields CL, Cebulla CM, Abdel-Rahman MH, Grossniklaus HE, Stern M-H, et al. Uveal melanoma. Nat Rev Dis Primers. 2020;6(1):24.
Article
PubMed
Google Scholar
Nayman T, Bostan C, Logan P, Burnier MN. Uveal melanoma risk factors: a systematic review of meta-analyses. Curr Eye Res. 2017;42(8):1085–93.
Article
PubMed
Google Scholar
Wakamatsu K, Hu D-N, McCormick SA, Ito S. Characterization of melanin in human iridal and choroidal melanocytes from eyes with various colored irides. Pigment Cell Melanoma Res. 2007;21(1):97–105.
Article
CAS
Google Scholar
Mäkitie T, Summanen P, Tarkkanen A, Kivelä T. Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2001;42(7):1414–21.
PubMed
Google Scholar
Horsman DE, Sroka H, Rootman J, White VA. Monosomy 3 and isochromosome 8q in a uveal melanoma. Cancer Genet Cytogenet. 1990;45(2):249–53.
Article
CAS
PubMed
Google Scholar
Harbour JW, Onken MD, Roberson EDO, Duan S, Cao L, Worley LA, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 2010;330(6009):1410–3.
Article
CAS
PubMed
PubMed Central
Google Scholar
Yavuzyigitoglu S, Koopmans AE, Verdijk RM, Vaarwater J, Eussen B, van Bodegom A, et al. Uveal melanomas with SF3B1 mutations. Ophthalmology. 2016;123(5):1118–28.
Article
PubMed
Google Scholar
Ewens KG, Kanetsky PA, Richards-Yutz J, Purrazzella J, Shields CL, Ganguly T, et al. Chromosome 3 status combined with BAP1 and EIF1AX mutation profiles are associated with metastasis in uveal melanoma. Investig Opthalmol Visual Sci. 2014;55(8):5160.
Article
CAS
Google Scholar
Vader MJC, Madigan MC, Versluis M, Suleiman HM, Gezgin G, Gruis NA, et al. GNAQ and GNA11 mutations and downstream YAP activation in choroidal nevi. Br J Cancer. 2017;117(6):884–7.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kujala E, Mäkitie T, Kivela T. Very long-term prognosis of patients with malignant uveal melanoma. Investig Opthalmol Visual Sci. 2003;44(11):4651.
Article
Google Scholar
Eagle RC. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma. Arch Ophthalmol. 2006;124(12):1684.
Article
Google Scholar
Melia BM, Abramson DH, Albert DM, Boldt HC, Earle JD, Hanson WF, Montague P, Moy CS, Schachat AP, Simpson ER, Straatsma BR, Vine AK, Weingeist TA. Collaborative ocular melanoma study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma I. visual acuity after 3 years COMS report no. 16. Ophthalmology. 2001;108(2):348–66.
Eide N, Hoifødt HK, Nesland JM, Faye RS, Qvale GA, Faber RT, et al. Disseminated tumour cells in bone marrow of patients with uveal melanoma. Acta Ophthalmol. 2013;91(4):343–8.
Article
PubMed
Google Scholar
Yu G, Jing Y, Kou X, Ye F, Gao L, Fan Q, et al. Hepatic stellate cells secreted hepatocyte growth factor contributes to the chemoresistance of hepatocellular carcinoma. PLoS One. 2013;8(9):e73312.
Article
CAS
PubMed
PubMed Central
Google Scholar
Singh AD. Uveal melanoma: implications of tumor doubling time. Ophthalmology. 2001;108(5):829–30.
Article
CAS
PubMed
Google Scholar
Uner OE, See TRO, Szalai E, Grossniklaus HE, Stålhammar G. Author correction: estimation of the timing of BAP1 mutation in uveal melanoma progression. Sci Rep. 2021;11(1):17036.
Article
CAS
PubMed
PubMed Central
Google Scholar
Grossniklaus HE. Understanding uveal melanoma metastasis to the liver: the Zimmerman effect and the Zimmerman hypothesis. Ophthalmology. 2019;126(4):483–7.
Article
PubMed
Google Scholar
Kubatka P, Zubor P, Busselberg D, Kwon TK, Adamek M, Petrovic D, et al. Melatonin and breast cancer: evidences from preclinical and human studies. Crit Rev Oncol Hematol. 2018;122:133–43.
Article
PubMed
Google Scholar
Anisimov VN, Popovich IG, Shtylik AV, Zabezhinski MA, Ben-Huh H, Gurevich P, et al. Melatonin and colon carcinogenesis. Exp Toxicol Pathol. 2000;52(1):71–6.
Article
CAS
PubMed
Google Scholar
Wang S, Tai H, Tang C, Lin L, Lin T, Chang A, et al. Melatonin impedes prostate cancer metastasis by suppressing MMP-13 expression. J Cell Physiol. 2021;236(5):3979–90.
Article
CAS
PubMed
Google Scholar
Fernández-Palanca P, Méndez-Blanco C, Fondevila F, Tuñón MJ, Reiter RJ, Mauriz JL, et al. Melatonin as an antitumor agent against liver cancer: an updated systematic review. Antioxidants. 2021;10(1):103.
Article
CAS
PubMed
PubMed Central
Google Scholar
Galien. Galen on the usefulness of the parts of the body: De Usu Partium; 1968.
Google Scholar
McCord CP, Allen FP. Evidences associating pineal gland function with alterations in pigmentation. J Exp Zool. 1917;23(1):207–24.
Article
CAS
Google Scholar
Lerner AB, Case JD, Takahashi Y, Lee TH, Mori W. Isolation of melatonin, the pineal gland factor that lightens melanocytes. J Am Chem Soc. 1958;80(10):2587.
Article
CAS
Google Scholar
Slominski A, Fischer TW, Zmijewski MA, Wortsman J, Semak I, Zbytek B, et al. On the role of melatonin in skin physiology and pathology. Endocrine. 2005;27(2):137–48.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bubenik GA. Gastrointestinal melatonin: localization, function, and clinical relevance. Dig Dis Sci. 2002;47(10):2336–48.
Article
CAS
PubMed
Google Scholar
Cahill GM, Besharse JC. Circadian clock functions localized in xenopus retinal photoreceptors. Neuron. 1993;10(4):573–7.
Article
CAS
PubMed
Google Scholar
Conti A, Conconi S, Hertens E, Skwarlo-Sonta K, Markowska M, Maestroni GJM. Evidence for melatonin synthesis in mouse and human bone marrow cells. J Pineal Res. 2000;28(4):193–202.
Article
CAS
PubMed
Google Scholar
Tan D, Xu B, Zhou X, Reiter R. Pineal calcification, melatonin production, aging, associated health consequences and rejuvenation of the pineal gland. Molecules. 2018;23(2):301.
Article
CAS
PubMed Central
Google Scholar
Tan D-X, RusselJ R. Mitochondria: the birth place, battle ground and the site of melatonin metabolism in cells. Melatonin Res. 2019;2(1):44–66.
Article
Google Scholar
Axelrod J, Weissbach H. Enzymatic O-methylation of N-Acetylserotonin to melatonin. Science. 1960;131(3409):1312.
Article
CAS
PubMed
Google Scholar
Weissbach H, Redfield BG, Axelrod J. Biosynthesis of melatonin: enzymic conversion of serotonin to N-acetylserotonin. Biochim Biophys Acta. 1960;43:352–3.
Article
CAS
PubMed
Google Scholar
Tricoire H, Møller M, Chemineau P, Malpaux B. Origin of cerebrospinal fluid melatonin and possible function in the integration of photoperiod. Reprod (Cambridge, England) Supplement. 2003;61:311–21.
CAS
Google Scholar
Zhao D, Yu Y, Shen Y, Liu Q, Zhao Z, Sharma R, et al. Melatonin synthesis and function: evolutionary history in animals and plants. Front Endocrinol. 2019;10.
Maestroni GJM. The immunoneuroendocrine role of melatonin. J Pineal Res. 1993;14(1):1–10.
Article
CAS
PubMed
Google Scholar
Claustrat B, Leston J. Melatonin: physiological effects in humans. Neurochirurgie. 2015;61(2–3):77–84.
Article
CAS
PubMed
Google Scholar
Tan D-X, Manchester LC, Hardeland R, Lopez-Burillo S, Mayo JC, Sainz RM, et al. Melatonin: a hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin. J Pineal Res. 2003;34(1):75–8.
Article
CAS
PubMed
Google Scholar
Tan D, Chen LD, Poeggeler B, Manchester LC, Reiter RJ. Melatonin: a potent endogenous hydroxyl radical scavenger. Endocr J. 1993;1:57–60.
Google Scholar
Tan D-X, Manchester LC, Reiter RJ, Qi W-B, Karbownik M, Calvo JR. Significance of melatonin in antioxidative defense system: reactions and products. Neurosignals. 2000;9(3–4):137–59.
Article
CAS
Google Scholar
Nelson RJ, Chbeir S. Dark matters: effects of light at night on metabolism. Proc Nutr Soc. 2018;77(3):223–9.
Article
PubMed
PubMed Central
Google Scholar
Hattar S, Liao H-W, Takao M, Berson DM, Yau K-W. Melanopsin-containing retinal ganglion cells: architecture, projections, and intrinsic photosensitivity. Science. 2002;295(5557):1065–70.
Article
CAS
PubMed
PubMed Central
Google Scholar
Borjigin J, Samantha Zhang L, Calinescu A-A. Circadian regulation of pineal gland rhythmicity. Mol Cell Endocrinol. 2012;349(1):13–9.
Article
CAS
PubMed
Google Scholar
Brzezinski A. Melatonin in humans. N Engl J Med. 1997;336(3):186–95.
Article
CAS
PubMed
Google Scholar
Waldhauser F, Frisch H, Waldhauser M, Weiszenbacher G, Zeitlhuber U, RichardJ W. Fall in nocturnal serum melatonin during prepuberty and pubescense. Lancet. 1984;323(8373):362–5.
Article
Google Scholar
Rossignol D, Frye R. Melatonin in autism spectrum disorders: a systematic review and meta-analysis. Dev Med Child Neurol. 2011;53(9):783–92.
Article
PubMed
Google Scholar
Sadat-Ali M, Al-Habdan I, Al-Othman A. Adolescent idiopathic scoliosis. Is low melatonin a cause? Joint Bone Spine. 2000;67(1):62–4.
CAS
PubMed
Google Scholar
Zhou J-N, Liu R-Y, Kamphorst W, Hofman MA, Swaab DF. Early neuropathological Alzheimer’s changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. J Pineal Res. 2003;35(2):125–30.
Article
CAS
PubMed
Google Scholar
Brown RP, Kocsis JH, Caroff S, Amsterdam J, Winokur A, Stokes P, et al. Depressed mood and reality disturbance correlate with decreased nocturnal melatonin in depressed patients. Acta Psychiatr Scand. 1987;76(3):272–5.
Article
CAS
PubMed
Google Scholar
Rosen R, Hu D-N, Perez V, Tai K, Yu G-P, Chen M, et al. Urinary 6-sulfatoxymelatonin level in age-related macular degeneration patients. Mol Vis. 2009;15:1673–9.
CAS
PubMed
PubMed Central
Google Scholar
Tordjman S, Chokron S, Delorme R, Charrier A, Bellissant E, Jaafari N, et al. Melatonin: pharmacology, functions and therapeutic benefits. Curr Neuropharmacol. 2017;15(3):434–43.
Article
CAS
PubMed
PubMed Central
Google Scholar
Mills E, Wu P, Seely D, Guyatt G. Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis. J Pineal Res. 2005;39(4):360–6.
Article
CAS
PubMed
Google Scholar
Andersen LPH, Werner MU, Rosenkilde MM, Harpsøe NG, Fuglsang H, Rosenberg J, et al. Pharmacokinetics of oral and intravenous melatonin in healthy volunteers. BMC Pharmacol Toxicol. 2016;17(1):8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zimmermann RC, McDougle CJ, Schumacher M, Olcese J, Heninger GR, Price LH. Urinary 6-hydroxymelatonin sulfate as a measure of melatonin secretion during acute tryptophan depletion. Psychoneuroendocrinology. 1993;18(8):567–78.
Article
CAS
PubMed
Google Scholar
Cardinali DP, Golombek DA, Rosenstein RE, Cutrera RA, Esquifino AI. Melatonin site and mechanism of action: single or multiple? J Pineal Res. 1997;23(1):32–9.
Article
CAS
PubMed
Google Scholar
Aust S, Thalhammer T, Humpeler S, Jager W, Klimpfinger M, Tucek G, et al. The melatonin receptor subtype MT1 is expressed in human gallbladder epithelia. J Pineal Res. 2004;36(1):43–8.
Article
CAS
PubMed
Google Scholar
Fischer TW, Slominski A, Zmijewski MA, Reiter RJ, Paus R. Melatonin as a major skin protectant: from free radical scavenging to DNA damage repair. Exp Dermatol. 2008;17(9):713–30.
Article
CAS
PubMed
Google Scholar
Dubocovich ML, Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine. 2005;27(2):101–10.
Article
CAS
PubMed
Google Scholar
Pandi-Perumal SR, Trakht I, Srinivasan V, Spence DW, Maestroni GJM, Zisapel N, et al. Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. Prog Neurobiol. 2008;85(3):335–53.
Article
CAS
PubMed
Google Scholar
Slominski A, Wortsman J, Tobin DJ. The cutaneous serotoninergic/melatoninergic system: securing a place under the sun. FASEB J. 2005;19(2):176–94.
Article
CAS
PubMed
Google Scholar
Jockers R, Maurice P, Boutin JA, Delagrange P. Melatonin receptors, heterodimerization, signal transduction and binding sites: what’s new? Br J Pharmacol. 2008;154(6):1182–95.
Article
CAS
PubMed
PubMed Central
Google Scholar
Savaskan E, Ayoub MA, Ravid R, Angeloni D, Fraschini F, Meier F, et al. Reduced hippocampal MT2 melatonin receptor expression in Alzheimer’s disease. J Pineal Res. 2005;38(1):10–6.
Article
CAS
PubMed
Google Scholar
Brunner P, Sözer-Topcular N, Jockers R, Ravid R, Angeloni D, Fraschini F, et al. Pineal and cortical melatonin receptors MT1 and MT2 are decreased in Alzheimer’s disease. Eur J Histochem. 2007;50(4):311–6.
Google Scholar
Reppert SM, Godson C, Mahle CD, Weaver DR, Slaugenhaupt SA, Gusella JF. Molecular characterization of a second melatonin receptor expressed in human retina and brain: the Mel1b melatonin receptor. Proc Natl Acad Sci. 1995;92(19):8734–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Slaugenhaupt SA, Roca AL, Liebert CB, Altherr MR, Gusella JF, Reppert SM. Mapping of the gene for the mel1a-melatonin receptor to human chromosome 4 (MTNR1A) and mouse chromosome 8 (Mtnr1a). Genomics. 1995;27(2):355–7.
Article
CAS
PubMed
Google Scholar
Duncan MJ, Takahashi JS, Dubocovich ML. 2-[125I]iodomelatonin binding sites in hamster brain membranes: pharmacological characteristics and regional distribution*. Endocrinology. 1988;122(5):1825–33.
Article
CAS
PubMed
Google Scholar
Zhao Q, Yang XL, Holtzclaw WD, Talalay P. Unexpected genetic and structural relationships of a long-forgotten flavoenzyme to NAD(P)H:quinone reductase (DT-diaphorase). Proc Natl Acad Sci. 1997;94(5):1669–74.
Article
CAS
PubMed
PubMed Central
Google Scholar
Nosjean O, Ferro M, Cogé F, Beauverger P, Henlin J-M, Lefoulon F, et al. Identification of the melatonin-binding SiteMT 3 as the Quinone reductase 2. J Biol Chem. 2000;275(40):31311–7.
Article
CAS
PubMed
Google Scholar
Smirnov AN. Nuclear melatonin receptors. Biochemistry (Mosc). 2001;66(1):19–26.
Article
CAS
Google Scholar
Dai J, Ram PT, Yuan L, Spriggs LL, Hill SM. Transcriptional repression of RORα activity in human breast cancer cells by melatonin. Mol Cell Endocrinol. 2001;176(1–2):111–20.
Article
CAS
PubMed
Google Scholar
Hevia D, González-Menéndez P, Quiros-González I, Miar A, Rodríguez-García A, Tan D-X, et al. Melatonin uptake through glucose transporters: a new target for melatonin inhibition of cancer. J Pineal Res. 2015;58(2):234–50.
Article
CAS
PubMed
Google Scholar
Dubocovich ML. Melatonin receptors: role on sleep and circadian rhythm regulation. Sleep Med. 2007;8:34–42.
Article
PubMed
Google Scholar
Liu C, Weaver DR, Jin X, Shearman LP, Pieschl RL, Gribkoff VK, et al. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron. 1997;19(1):91–102.
Article
CAS
PubMed
Google Scholar
Gobbi G, Comai S. Differential function of melatonin MT1 and MT2 receptors in REM and NREM sleep. Front Endocrinol. 2019;10.
Niles LP, Armstrong KJ, Rincón Castro L, Dao CV, Sharma R, McMillan CR, et al. Neural stem cells express melatonin receptors and neurotrophic factors: colocalization of the MT 1 receptor with neuronal and glial markers. BMC Neurosci. 2004;5(1):41.
Article
CAS
PubMed
PubMed Central
Google Scholar
Luboshitzky R, Lavie P. Melatonin and sex hormone interrelationships - a review. J Pediatr Endocrinol Metab. 1999;12(3):355-62.
Crowley SJ, Acebo C, Carskadon MA. Human puberty: salivary melatonin profiles in constant conditions. Dev Psychobiol. 2012;54(4):468–73.
Article
CAS
PubMed
Google Scholar
Imenshahidi M, Karimi G, Hosseinzadeh H. Effects of melatonin on cardiovascular risk factors and metabolic syndrome: a comprehensive review. Naunyn Schmiedebergs Arch Pharmacol. 2020;393(4):521–36.
Article
CAS
PubMed
Google Scholar
Celinski K, Konturek PC, Slomka M, Cichoz-Lach H, Brzozowski T, Konturek SJ. Effects of treatment with melatonin and tryptophan on liver enzymes, parameters of fat metabolism and plasma levels of cytokines in patients with non-alcoholic fatty liver disease--14 months follow up. J Physiol Pharmacol. 2014;65:75–82.
CAS
PubMed
Google Scholar
Scheer FAJL, van Montfrans GA, van Someren EJW, Mairuhu G, Buijs RM. Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension. Hypertension. 2004;43(2):192–7.
Article
CAS
PubMed
Google Scholar
Mansouri A, Demeilliers C, Amsellem S, Pessayre D, Fromenty B. Acute ethanol administration oxidatively damages and depletes mitochondrial dna in mouse liver, brain, heart, and skeletal muscles: protective effects of antioxidants. J Pharmacol Exp Ther. 2001;298(2):737–43.
CAS
PubMed
Google Scholar
Tan D, Reiter R, Manchester L, Yan M, El-Sawi M, Sainz R, et al. Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr Top Med Chem. 2002;2(2):181–97.
Article
CAS
PubMed
Google Scholar
Reiter RJ, Calvo JR, Karbownik M, Qi W, Tan DX. Melatonin and its relation to the immune system and inflammation. Ann N Y Acad Sci. 2006;917(1):376–86.
Article
Google Scholar
Srinivasan V, Pandi-Perumal SR, Maestroni GJM, Esquifino AI, Hardeland R, Cardinali DP. Role of melatonin in neurodegenerative diseases. Neurotox Res. 2005;7(4):293–318.
Article
CAS
PubMed
Google Scholar
Miller SC, Pandi PSR, Esquifino AI, Cardinali DP, Maestroni GJM. The role of melatonin in immuno-enhancement: potential application in cancer. Int J Exp Pathol. 2006;87(2):81–7.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sompol P, Liu X, Baba K, Paul KN, Tosini G, Iuvone PM, et al. N-acetylserotonin promotes hippocampal neuroprogenitor cell proliferation in sleep-deprived mice. Proc Natl Acad Sci. 2011;108(21):8844–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Buchanan KL, Yellon SM. Delayed puberty in the male Djungarian hamster: effect of short photoperiod or melatonin treatment on the GnRH neuronal system. Neuroendocrinology. 1991;54(2):96–102.
Article
CAS
PubMed
Google Scholar
Boafo A, Greenham S, Alenezi S, Robillard R, Pajer K, Tavakoli P, et al. Could long-term administration of melatonin to prepubertal children affect timing of puberty? A clinician’s perspective. Nat Sci Sleep. 2019;11:1–10.
Article
PubMed
PubMed Central
Google Scholar
Simko F, Pechanova O, Repova Bednarova K, Krajcirovicova K, Celec P, Kamodyova N, et al. Hypertension and cardiovascular remodelling in rats exposed to continuous light: protection by ACE-inhibition and melatonin. Mediators Inflamm. 2014;2014:1–10.
Article
CAS
Google Scholar
Wessely A, Steeb T, Erdmann M, Heinzerling L, Vera J, Schlaak M, et al. The role of immune checkpoint blockade in uveal melanoma. Int J Mol Sci. 2020;21(3):879.
Article
CAS
PubMed Central
Google Scholar
Stålhammar G, Seregard S, Grossniklaus HE. Expression of immune checkpoint receptors Indoleamine 2,3-dioxygenase and T cell Ig and ITIM domain in metastatic versus nonmetastatic choroidal melanoma. Cancer Med. 2019;8:2784–92.
PubMed
PubMed Central
Google Scholar
Javed A, Milhem M. Role of natural killer cells in uveal melanoma. Cancers. 2020;12(12):3694.
Article
CAS
PubMed Central
Google Scholar
Reiter RJ, Rosales-Corral S, Tan DX, Jou MJ, Galano A, Xu B. Melatonin as a mitochondria-targeted antioxidant: one of evolution’s best ideas. Cell Mol Life Sci. 2017;74(21):3863–81.
Article
CAS
PubMed
Google Scholar
Mediavilla M, Sanchez-Barcelo E, Tan D, Manchester L, Reiter R. Basic mechanisms involved in the anti-cancer effects of melatonin. Curr Med Chem. 2010;17(36):4462–81.
Article
CAS
PubMed
Google Scholar
Qi X, Wang J. Melatonin improves mitochondrial biogenesis through the AMPK/PGC1α pathway to attenuate ischemia/reperfusion-induced myocardial damage. Aging. 2020;12(8):7299–312.
Article
CAS
PubMed
PubMed Central
Google Scholar
Martin M, Macıas M, León J, Escames G, Khaldy H, Acuña-Castroviejo D. Melatonin increases the activity of the oxidative phosphorylation enzymes and the production of ATP in rat brain and liver mitochondria. Int J Biochem Cell Biol. 2002;34(4):348–57.
Article
CAS
PubMed
Google Scholar
Yamamoto H, Tang H. Preventive effect of melatonin against cyanide-induced seizures and lipid peroxidation in mice. Neurosci Lett. 1996;207(2):89–92.
Article
CAS
PubMed
Google Scholar
Owino S, Contreras-Alcantara S, Baba K, Tosini G. Melatonin signaling controls the daily rhythm in blood glucose levels independent of peripheral clocks. PLoS One. 2016;11(1):e0148214.
Article
CAS
PubMed
PubMed Central
Google Scholar
Peschke E, Mühlbauer E, Mußhoff U, Csernus VJ, Chankiewitz E, Peschke D. Receptor (MT1) mediated influence of melatonin on cAMP concentration and insulin secretion of rat insulinoma cells INS-1. J Pineal Res. 2002;33(2):63–71.
Article
CAS
PubMed
Google Scholar
Stumpf I, Mühlbauer E, Peschke E. Involvement of the cGMP pathway in mediating the insulin-inhibitory effect of melatonin in pancreatic β-cells. J Pineal Res. 2008;45(3):318–27.
Article
CAS
PubMed
Google Scholar
Bähr I, Mühlbauer E, Albrecht E, Peschke E. Evidence of the receptor-mediated influence of melatonin on pancreatic glucagon secretion via the Gαq protein-coupled and PI3K signaling pathways. J Pineal Res. 2012;53(4):390–8.
Article
CAS
PubMed
Google Scholar
la Fleur SE, Kalsbeek A, Wortel J, van der Vliet J, Buijs RM. Role for the pineal and melatonin in glucose homeostasis: pinealectomy increases night-time glucose concentrations. J Neuroendocrinol. 2001;13(12):1025–32.
Article
PubMed
Google Scholar
Mühlbauer E, Gross E, Labucay K, Wolgast S, Peschke E. Loss of melatonin signalling and its impact on circadian rhythms in mouse organs regulating blood glucose. Eur J Pharmacol. 2009;606(1–3):61–71.
Article
CAS
PubMed
Google Scholar
Lissoni P, Barni S, Ardizzoia A, Tancini G, Conti A, Maestroni G. A randomized study with the pineal hormone melatonin versus supportive care alone in patients with brain metastases due to solid neoplasms. Cancer. 1994;73(3):699–701.
Article
CAS
PubMed
Google Scholar
Robinson WA, Dreiling L, Gonzalez R, Balmer C. Treatment of human metastatic malignant melanoma with high dose oral melatonin. In: The pineal gland and its hormones. Boston: Springer US; 1995. p. 219–25.
Chapter
Google Scholar
Lissoni P, Barni S, Mandalà M, Ardizzoia A, Paolorossi F, Vaghi M, et al. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Cancer. 1999;35(12):1688–92.
Article
CAS
PubMed
Google Scholar
Lissoni P, Barni S, Fossati V, Ardizzoia A, Cazzaniga M, Tancini G, et al. A randomized study of neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin compared to supportive care alone in patients with untreatable metastatic solid tumour. Support Care Cancer. 1995;3(3):194–7.
Article
CAS
PubMed
Google Scholar
Lissoni P, Meregalli S, Nosetto L, Barni S, Tancini G, Fossati V, et al. Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone. Oncology. 1996;53(1):43–6.
Article
CAS
PubMed
Google Scholar
Lissoni P, Barni S, Meregalli S, Fossati V, Cazzaniga M, Esposti D, et al. Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. Br J Cancer. 1995;71(4):854–6.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kanishi Y, Kobayashi Y, Noda S, Ishizuka B, Saito K. Differential growth inhibitory effect of melatonin on two endometrial cancer cell lines. J Pineal Res. 2000;28(4):227–33.
Article
CAS
PubMed
Google Scholar
Petranka J, Baldwin W, Biermann J, Jayadev S, Barrett JC, Murphy E. The oncostatic action of melatonin in an ovarian carcinoma cell line. J Pineal Res. 1999;26(3):129–36.
Article
CAS
PubMed
Google Scholar
Najafi M, Salehi E, Farhood B, Nashtaei MS, Hashemi Goradel N, Khanlarkhani N, et al. Adjuvant chemotherapy with melatonin for targeting human cancers: a review. J Cell Physiol. 2019;234(3):2356–72.
Article
CAS
PubMed
Google Scholar
Najafi M, Shirazi A, Motevaseli E, Geraily G, Norouzi F, Heidari M, et al. The melatonin immunomodulatory actions in radiotherapy. Biophys Rev. 2017;9(2):139–48.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wang Y, Jin B, Ai F, Duan C, Lu Y, Dong T, et al. The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-analysis of randomized controlled trials. Cancer Chemother Pharmacol. 2012;69(5):1213–20.
Article
CAS
PubMed
Google Scholar
Shen Y-Q, Guerra-Librero A, Fernandez-Gil BI, Florido J, García-López S, Martinez-Ruiz L, et al. Combination of melatonin and rapamycin for head and neck cancer therapy: suppression of AKT/mTOR pathway activation, and activation of mitophagy and apoptosis via mitochondrial function regulation. J Pineal Res. 2018;64(3):e12461.
Article
CAS
Google Scholar
Lissoni P. Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms. Pathol Biol. 2007;55(3–4):201–4.
Article
CAS
PubMed
Google Scholar
Alonso-González C, Menéndez-Menéndez J, González-González A, González A, Cos S, Martínez-Campa C. Melatonin enhances the apoptotic effects and modulates the changes in gene expression induced by docetaxel in MCF-7 human breast cancer cells. Int J Oncol. 2018;52(2):560–70.
PubMed
Google Scholar
Reiter R, Rosales-Corral S, Tan D-X, Acuna-Castroviejo D, Qin L, Yang S-F, et al. Melatonin, a full service anti-cancer agent: inhibition of initiation, progression and metastasis. Int J Mol Sci. 2017;18(4):843.
Article
CAS
PubMed Central
Google Scholar
Casado-Zapico S, Rodriguez-Blanco J, GarcÃa-Santos G, MartÃn V, Sánchez‐Sánchez AM, Antolín I, et al. Synergistic antitumor effect of melatonin with several chemotherapeutic drugs on human Ewing sarcoma cancer cells: potentiation of the extrinsic apoptotic pathway. J Pineal Res. 2010;48(1):72–80.
Article
CAS
PubMed
Google Scholar
Menashe J. Managing and avoiding bortezomib toxicity. Commun Oncol. 2007;4(8):480–4.
Article
Google Scholar
Koşar PA, Nazıroğlu M, Övey İS, Çiğ B. Synergic effects of doxorubicin and melatonin on apoptosis and mitochondrial oxidative stress in MCF-7 breast cancer cells: involvement of TRPV1 channels. J Membr Biol. 2016;249(1–2):129–40.
Article
CAS
PubMed
Google Scholar
Kim J-H, Jeong S-J, Kim B, Yun S-M, Choi DY, Kim S-H. Melatonin synergistically enhances cisplatin-induced apoptosis via the dephosphorylation of ERK/p90 ribosomal S6 kinase/heat shock protein 27 in SK-OV-3 cells. J Pineal Res. 2012;52(2):244–52.
Article
CAS
PubMed
Google Scholar
Slominski A, Pruski D. Melatonin inhibits proliferation and melanogenesis in rodent melanoma cells. Exp Cell Res. 1993;206(2):189–94.
Article
CAS
PubMed
Google Scholar
Cos S, Garcia-Bolado A, Sánchez-Barceló EJ. Direct antiproliferative effects of melatonin on two metastatic cell sublines of mouse melanoma (B16BL6 and PG19). Melanoma Res. 2001;11(2):197–201.
Article
CAS
PubMed
Google Scholar
Fischer T, Zmijewski M, Zbytek B, Sweatman T, Slominski R, Wortsman J, et al. Oncostatic effects of the indole melatonin and expression of its cytosolic and nuclear receptors in cultured human melanoma cell lines. Int J Oncol. 2006;29(3):665–72.
CAS
PubMed
Google Scholar
Sardo FL, Muti P, Blandino G, Strano S. Melatonin and hippo pathway: is there existing cross-talk? Int J Mol Sci. 2017;18(9):1913.
Article
CAS
PubMed Central
Google Scholar
Santoro R, Marani M, Blandino G, Muti P, Strano S. Melatonin triggers p53Ser phosphorylation and prevents DNA damage accumulation. Oncogene. 2012;31(24):2931–42.
Article
CAS
PubMed
Google Scholar
Zhou Q, Gui S, Zhou Q, Wang Y. Melatonin inhibits the migration of human lung adenocarcinoma A549 cell lines involving JNK/MAPK pathway. PLoS One. 2014;9(7).
Cos S, Fernández R, Güézmes A, Sánchez-Barceló EJ. Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells. Cancer Res. 1998;58(19):4383–90.
CAS
PubMed
Google Scholar
Borin TF, Arbab AS, Gelaleti GB, Ferreira LC, Moschetta MG, Jardim-Perassi BV, et al. Melatonin decreases breast cancer metastasis by modulating rho-associated kinase protein-1 expression. J Pineal Res. 2016;60(1):3–15.
Article
CAS
PubMed
Google Scholar
Liu S, Goldstein RH, Scepansky EM, Rosenblatt M. Inhibition of rho-associated kinase signaling prevents breast cancer metastasis to human bone. Cancer Res. 2009;69(22):8742–51.
Article
CAS
PubMed
Google Scholar
Tobioka H, Isomura H, Kokai Y, Tokunaga Y, Yamaguchi J, Sawada N. Occludin expression decreases with the progression of human endometrial carcinoma. Hum Pathol. 2004;35(2):159–64.
Article
CAS
PubMed
Google Scholar
Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev. 1992;13(1):18–32.
Article
CAS
PubMed
Google Scholar
Salven P, Mänpää H, Orpana A, Alitalo K, Joensuu H. Serum vascular endothelial growth factor is often elevated in disseminated cancer. Clin Cancer Res. 1997;3(5):647–51.
CAS
PubMed
Google Scholar
Fandrey J, Genius J. Reactive oxygen species as regulators of oxygen dependent gene expression. Adv Exp Med Biol. 2000;475:153–9.
Article
CAS
PubMed
Google Scholar
Dai M, Cui P, Yu M, Han J, Li H, Xiu R. Melatonin modulates the expression of VEGF and HIF-1α induced by CoCl 2 in cultured cancer cells. J Pineal Res. 2008;44(2):121–6.
Article
CAS
PubMed
Google Scholar
Cheng J, Yang H, Gu C, Liu Y, Shao J, Zhu R, et al. Melatonin restricts the viability and angiogenesis of vascular endothelial cells by suppressing HIF-1α/ROS/VEGF. Int J Mol Med. 2019;43:945–55.
CAS
PubMed
Google Scholar
Wang R-X, Liu H, Xu L, Zhang H, Zhou R-X. Involvement of nuclear receptor RZR/RORγ in melatonin-induced HIF-1α inactivation in SGC-7901 human gastric cancer cells. Oncol Rep. 2015;34(5):2541–6.
Article
CAS
PubMed
Google Scholar
Wang R-X, Liu H, Xu L, Zhang H, Zhou R-X. Melatonin downregulates nuclear receptor RZR/RORγ expression causing growth-inhibitory and anti-angiogenesis activity in human gastric cancer cells in vitro and in vivo. Oncol Lett. 2016;12(2):897–903.
Article
CAS
PubMed
PubMed Central
Google Scholar
Dong L, You S, Zhang Q, Osuka S, Devi NS, Kaluz S, et al. Arylsulfonamide 64B inhibits hypoxia/HIF-induced expression of c-met and CXCR4 and reduces primary tumor growth and metastasis of uveal melanoma. Clin Cancer Res. 2019;25(7):2206–18.
Article
CAS
PubMed
Google Scholar
Schoenfield L, Janse S, Kline D, Aronow ME, Singh AD, Craven C, et al. Estrogen receptor is expressed in uveal melanoma: a potential target for therapy. Ocular Oncol Pathol. 2021;7(4):303–10.
Article
Google Scholar
Rato AG, Pedrero JG, Martínez MA, del Rio B, Lazo PS, Ramos S. Melatonin blocks the activation of estrogen receptor for DNA binding. FASEB J. 1999;13(8):857–68.
Article
CAS
PubMed
Google Scholar
Molis TM, Spriggs LL, Hill SM. Modulation of estrogen receptor mRNA expression by melatonin in MCF-7 human breast cancer cells. Mol Endocrinol. 1994;8(12):1681–90.
CAS
PubMed
Google Scholar
Lawson NO, Wee BEF, Blask DE, Castles CG, Spriggs LL, Hill SM. Melatonin decreases estrogen receptor expression in the medial preoptic area of inbred (LSH/SsLak) Golden hamsters. Biol Reprod. 1992;47(6):1082–90.
Article
CAS
PubMed
Google Scholar
Bouhoute A, Leclercq G. Modulation of estradiol and DNA binding to estrogen receptor upon association with calmodulin. Biochem Biophys Res Commun. 1995;208(2):748–55.
Article
CAS
PubMed
Google Scholar
Castoria G, Migliaccio A, Nola E, Auricchio F. In vitro interaction of estradiol receptor with Ca2+ −calmodulin. Mol Endocrinol. 1988;2(2):167–74.
Article
CAS
PubMed
Google Scholar
García Pedrero JM, del Rio B, Martínez-Campa C, Muramatsu M, Lazo PS, Ramos S. Calmodulin is a selective modulator of estrogen receptors. Mol Endocrinol. 2002;16(5):947–60.
Article
PubMed
Google Scholar
Hu D-N, Roberts JE. Melatonin inhibits growth of cultured human uveal melanoma cells. Melanoma Res. 1997;7(1):27–31.
Article
CAS
PubMed
Google Scholar
Hu DN, McCormick SA, Roberts JE. Effects of melatonin, its precursors and derivatives on the growth of cultured human uveal melanoma cells. Melanoma Res. 1998;8(3):205–10.
Article
CAS
PubMed
Google Scholar
Roberts JE, Wiechmann AF, Hu D-N. Melatonin receptors in human uveal melanocytes and melanoma cells. J Pineal Res. 2002;28(3):165–71.
Article
Google Scholar
Alvarez-Artime A, Cernuda-Cernuda R, Francisco-Artime-Naveda CV, Gonzalez-Menendez P, Fernadez-Vega S, et al. Melatonin-induced cytoskeleton reorganization leads to inhibition of melanoma cancer cell proliferation. Int J Mol Sci. 2020;21(2):548.
Article
CAS
PubMed Central
Google Scholar
Gatti G, Lucini V, Dugnani S, Calastretti A, Spadoni G, Bedini A, et al. Antiproliferative and pro-apoptotic activity of melatonin analogues on melanoma and breast cancer cells. Oncotarget. 2017;8(40):68338–53.
Article
PubMed
PubMed Central
Google Scholar
Narita T, Kudo H. Effect of melatonin on B16 melanoma growth in athymic mice. Cancer Res. 1985;45(9):4175–7.
CAS
PubMed
Google Scholar
Gonzalez R, Sanchez A, Ferguson JA, Balmer C, Daniel C, Cohn A, et al. Melatonin therapy of advanced human malignant melanoma. Melanoma Res. 1991;1(4):237–44.
Article
CAS
PubMed
Google Scholar
Kane MA, Johnson A, Nash AE, Boose D, Mathai G, Balmer C, et al. Serum melatonin levels in melanoma patients after repeated oral administration. Melanoma Res. 1994;4(1):59–65.
Article
CAS
PubMed
Google Scholar
Seely D, Legacy M, Auer RC, Fazekas A, Delic E, Anstee C, et al. Adjuvant melatonin for the prevention of recurrence and mortality following lung cancer resection (AMPLCaRe): a randomized placebo controlled clinical trial. EClinicalMedicine. 2021;33.
Hrushesky WJM, Lis CG, Levin RD, Grutsch JF, Birdsall T, Wood PA, et al. Daily evening melatonin prolongs survival among patients with advanced non-small-cell lung cancer. Biol Rhythm Res. 2021:1–15.
Uner OE, See TRO, Szalai E, Grossniklaus HE, Stålhammar G. Estimation of the timing of BAP1 mutation in uveal melanoma progression. Sci Rep. 2021;11(1):8923.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kartini D, Taher A, Panigoro SS, Setiabudy R, Jusman SW, Haryana SM, et al. Effect of melatonin supplementation in combination with neoadjuvant chemotherapy to miR-210 and CD44 expression and clinical response improvement in locally advanced oral squamous cell carcinoma: a randomized controlled trial. J Egypt Natl Canc Inst. 2020;32(1):12.
Article
PubMed
Google Scholar
Lissoni P, Chilelli M, Villa S, Cerizza L, Tancini G. Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial. J Pineal Res. 2003;35(1):12–5.
Article
CAS
PubMed
Google Scholar
Cerea G, Vaghi M, Ardizzoia A, Villa S, Bucovec R, Mengo S, et al. Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations. Anticancer Res. 2003;23(2C):1951–4.
Berk L, Berkey B, Rich T, Hrushesky W, Blask D, Gallagher M, et al. Randomized phase II trial of high-dose melatonin and radiation therapy for RPA class 2 patients with brain metastases (RTOG 0119). Int J Radiat Oncol Biol Phys. 2007;68(3):852–7.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lissoni P, Barni S, Cattaneo G, Tancini G, Esposti G, Esposti D, et al. Clinical results with the pineal hormone melatonin in advanced cancer resistant to standard antitumor therapies. Oncology. 1991;48(6):448–50.
Article
CAS
PubMed
Google Scholar
Lissoni P, Brivio O, Brivio F, Barni S, Tancini G, Crippa D, et al. Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma. J Pineal Res. 1996;21(4):239–42.
Article
CAS
PubMed
Google Scholar
Lissoni P, Brivio F, Fumagalli L, Messina G, Vigoré L, Parolini D, et al. Neuroimmunomodulation in medical oncology: application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors. Anticancer Res. 2008;28(2B):1377–81.
CAS
PubMed
Google Scholar
Lissoni P, Bolis S, Brivio F, Fumagalli L. A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies. Anticancer Res. 2000;20(3B):2103–5.
Yan J-J, Shen F, Wang K, Wu M-C. Patients with advanced primary hepatocellular carcinoma treated by melatonin and transcatheter arterial chemoembolization: a prospective study. Hepatobiliary Pancreat Dis Int. 2002;1(2):183–6.
PubMed
Google Scholar
Stålhammar G. Forty-year prognosis after plaque brachytherapy of uveal melanoma. Sci Rep. 2020;10(1):11297.
Article
CAS
PubMed
PubMed Central
Google Scholar
Augsburger JJ, Corrêa ZM, Shaikh AH. Effectiveness of treatments for metastatic uveal melanoma. Am J Ophthalmol. 2009;148(1):119–27.
Article
PubMed
Google Scholar
Nichols EE, Richmond A, Daniels AB. Micrometastatic dormancy in uveal melanoma: a comprehensive review of the evidence, mechanisms, and implications for future adjuvant therapies. Int Ophthalmol Clin. 2017;57(1):1–10.
Article
PubMed
Google Scholar